Your browser doesn't support javascript.
loading
Impact of metformin, statin, aspirin and insulin on the prognosis of uHCC patients receiving first line Lenvatinib or Atezolizumab plus Bevacizumab.
Rimini, Margherita; Montes, Margarida; Amadeo, Elisabeth; Vitiello, Francesco; Kudo, Masatoshi; Tada, Toshifumi; Suda, Goki; Shimose, Shigeo; Lonardi, Sara; Finkelmeier, Fabian; Salani, Francesca; Antonuzzo, Lorenzo; Marra, Fabio; Iavarone, Massimo; Cabibbo, Giuseppe; Foschi, Francesco Giuseppe; Silletta, Marianna; Sacco, Rodolfo; Rapposelli, Ilario Giovanni; Scartozzi, Mario; Nicoletta, Pella; Aldrighetti, Luca; Persano, Mara; Camera, Silvia; Rossari, Federico; Foti, Silvia; Kumada, Takashi; Hiraoka, Atsushi; Iwamoto, Hideki; Rizzato, Mario Domenico; Himmelsbach, Vera; Masi, Gianluca; Corradi, Mattia; Celsa, Ciro; Fabio, Conti; Frassineti, Giovanni Luca; Cascinu, Stefano; Casadei-Gardini, Andrea; Presa, Jose.
Afiliación
  • Rimini M; Department of Oncology, IRCCS San Raffaele Scientific Institute Hospital, Vita-Salute San Raffaele University, Milan, Italy.
  • Montes M; Vita-Salute University San Raffaele, Milan, Italy.
  • Amadeo E; Liver Unit-CHTMAD, Vila Real, Portugal.
  • Vitiello F; Department of Oncology, IRCCS San Raffaele Scientific Institute Hospital, Vita-Salute San Raffaele University, Milan, Italy.
  • Kudo M; Department of Oncology, IRCCS San Raffaele Scientific Institute Hospital, Vita-Salute San Raffaele University, Milan, Italy.
  • Tada T; Department of Gastroenterology and Hepatology, Faculty of Medicine, Kindai University, Higashiosaka, Japan.
  • Suda G; Department of Internal Medicine, Japanese Red Cross Himeji Hospital, Himeji, Japan.
  • Shimose S; Department of Gastroenterology and Hepatology, Graduate School of Medicine, Hokkaido University, North 15, West 7, Kita-ku, Sapporo, Hokkaido, 060-8638, Japan.
  • Lonardi S; Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Fukuoka, 830-0011, Japan.
  • Finkelmeier F; Oncology Unit 1, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
  • Salani F; Department of Internal Medicine 1, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.
  • Antonuzzo L; Unit of Medical Oncology 2, University Hospital of Pisa, Pisa, Italy.
  • Marra F; Clinical Oncology Unit, Careggi University Hospital, Florence, Italy.
  • Iavarone M; Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
  • Cabibbo G; Clinical Oncology Unit, Careggi University Hospital, Florence, Italy.
  • Foschi FG; Division of Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
  • Silletta M; Section of Gastroenterology and Hepatology, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, PROMISE, University of Palermo, Palermo, Italy.
  • Sacco R; Department of Internal Medicine, Ospedale degli Infermi di Faenza, Faenza, Emilia Romagna, Italy.
  • Rapposelli IG; Department of Medical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy.
  • Scartozzi M; Gastroenterology and Digestive Endoscopy Unit, Foggia University Hospital, Foggia, Puglia, Italy.
  • Nicoletta P; Medical Oncology Unit, IRST IRCCS, Meldola, Italy.
  • Aldrighetti L; Medical Oncology, University and University Hospital of Cagliari, Cagliari, Italy.
  • Persano M; Department of Oncology, ASUFC University Hospital, Udine, Italy.
  • Camera S; Hepato-Biliary Surgery Department, IRCCS San Raffaele Hospital, Milan, Italy.
  • Rossari F; Medical Oncology, University and University Hospital of Cagliari, Cagliari, Italy.
  • Foti S; Medical Oncology, University and University Hospital of Cagliari, Cagliari, Italy.
  • Kumada T; Department of Oncology, IRCCS San Raffaele Scientific Institute Hospital, Vita-Salute San Raffaele University, Milan, Italy.
  • Hiraoka A; Department of Oncology, IRCCS San Raffaele Scientific Institute Hospital, Vita-Salute San Raffaele University, Milan, Italy.
  • Iwamoto H; Department of Internal Medicine, Japanese Red Cross Himeji Hospital, Himeji, Japan.
  • Rizzato MD; Department of Internal Medicine, Japanese Red Cross Himeji Hospital, Himeji, Japan.
  • Himmelsbach V; Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Fukuoka, 830-0011, Japan.
  • Masi G; Oncology Unit 1, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
  • Corradi M; Department of Internal Medicine 1, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.
  • Celsa C; Unit of Medical Oncology 2, University Hospital of Pisa, Pisa, Italy.
  • Fabio C; Division of Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
  • Frassineti GL; Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.
  • Cascinu S; Section of Gastroenterology and Hepatology, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, PROMISE, University of Palermo, Palermo, Italy.
  • Casadei-Gardini A; Department of Internal Medicine, Ospedale degli Infermi di Faenza, Faenza, Emilia Romagna, Italy.
  • Presa J; Medical Oncology Unit, IRST IRCCS, Meldola, Italy.
Sci Rep ; 14(1): 20200, 2024 08 30.
Article en En | MEDLINE | ID: mdl-39215078
ABSTRACT
Recently, in Hepatocellular carcinoma (HCC) setting, the use of metformin has been associated to a trend toward worse response rate, overall survival and progression free survival in patients who received immunotherapy. The study population included individuals from both Eastern and Western regions with a confirmed diagnosis of HCC and receiving first line treatment with Atezolizumab plus bevacizumab or Lenvatinib. Univariate and multivariate analyses were performed by Cox proportional. For the analysis, patients were stratified based on their use of concomitant medication or not. At the time of database lock, 319 deaths were observed 209 in the Lenvatinib cohort, 110 in the Atezolizumab plus bevacizumab cohort. In the Atezolizumab plus Bevacizumab arm, 50 (16.5%) patients were on chronic metformin use. At the univariate analysis for OS, patients who used metformin showed significantly shorter OS compared to patients who did not use metformin (HR 1.9, 95% CI 1.1-3.2). Multivariate analysis confirmed that patients in metformin group had significantly shorter OS compared to patients in no-metformin group (HR 1.9; 95% CI 1.1-3.1). At the univariate analysis for PFS, patients in metformin group had significantly shorter PFS compared to patients in no-metformin group (HR 1.6, 95% CI 1.0-2.6). Multivariate analysis confirmed that patients in metformin group had significantly shorter PFS compared to patients in no-metformin group (HR 1.7; 95% CI 1.1-2.7; p = 0.0147). No differences were reported in terms of ORR and DCR between patients in metformin group and those in no-metformin group. In the Lenvatinib cohort, 65 (15%) patients were recorded to chronically use metformin. No statistically significant differences in terms of both OS and PFS were found between patients in metformin group and patients in no-metformin group. This analysis unveils a negative prognostic role associated with metformin use specifically within the Atezolizumab plus Bevacizumab group.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Compuestos de Fenilurea / Quinolinas / Aspirina / Carcinoma Hepatocelular / Inhibidores de Hidroximetilglutaril-CoA Reductasas / Anticuerpos Monoclonales Humanizados / Bevacizumab / Insulina / Neoplasias Hepáticas / Metformina Límite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Sci Rep Año: 2024 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Compuestos de Fenilurea / Quinolinas / Aspirina / Carcinoma Hepatocelular / Inhibidores de Hidroximetilglutaril-CoA Reductasas / Anticuerpos Monoclonales Humanizados / Bevacizumab / Insulina / Neoplasias Hepáticas / Metformina Límite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Sci Rep Año: 2024 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Reino Unido